Cargando…
A Randomized, Controlled Trial of Treat-and-Extend vs. Pro Re Nata Regimen for Neovascular Age-Related Macular Degeneration
PURPOSE: To compare the efficacy and safety of conbercept using a treat-and-extend (T&E) regimen vs. a pro re nata (PRN) regimen in Chinese patients with neovascular age-related macular degeneration (nAMD). METHODS: This was a randomized, multicenter, non-inferiority study. After an initial load...
Autores principales: | Jia, Huixun, Lu, Bing, Yuan, Yuanzhi, Yuan, Fei, Li, Lei, Song, Yanping, Rong, Ao, Zhou, Minwen, Wang, Fenghua, Sun, Xiaodong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251380/ https://www.ncbi.nlm.nih.gov/pubmed/35795633 http://dx.doi.org/10.3389/fmed.2022.852519 |
Ejemplares similares
-
One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial
por: Wang, Fenghua, et al.
Publicado: (2019) -
Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol
por: Lin, Tiezhu, et al.
Publicado: (2020) -
Pro re nata versus fixed aflibercept regimen for neovascular age-related macular degeneration: a systematic review and meta-analysis
por: Victor, Andi Arus, et al.
Publicado: (2022) -
Ten-year real-world outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration using pro re nata regimen
por: Hujanen, Pekko, et al.
Publicado: (2023) -
Treat-and-Extend vs. Pro Re Nata Regimen of Ranibizumab for Diabetic Macular Edema—A Two-Year Matched Comparative Study
por: Lai, Tso-Ting, et al.
Publicado: (2022)